Related Experiment Video
Updated: Jul 2, 2026
10:43
Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids
Published on: December 23, 2022
Targeting Eg5 with K858: A Strategy for Radiosensitization Through ROS-Mediated DNA Damage in Esophageal Squamous
Ruixue Liu1, Shuo Zhou2, Feng Xiao1
1Department of Nuclear Medicine, Affiliated Hospital of Yangzhou University, Yangzhou University, 368 Hanjiang Middle Road, Yangzhou, Jiangsu, China.
Anti-Cancer Agents in Medicinal Chemistry
|July 1, 2026
Summary
The kinesin Eg5 protein is overexpressed in esophageal squamous cell carcinoma (ESCC). Inhibiting Eg5 with K858 enhances radiotherapy by increasing oxidative stress and DNA damage, offering a new treatment strategy for ESCC.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Radiotherapy resistance is a significant challenge in treating esophageal squamous cell carcinoma (ESCC).
- The kinesin Eg5 protein is overexpressed in various human cancers, including ESCC, and is a potential therapeutic target.
- The Eg5 inhibitor K858 shows potential in combination with radiotherapy, but its mechanism involving reactive oxygen species (ROS) and DNA damage requires elucidation.
Purpose of the Study:
- To determine the clinical significance of Eg5 in ESCC.
- To investigate if K858 enhances radiosensitivity in ESCC through ROS-mediated DNA damage.
- To explore Eg5 as a prognostic biomarker and therapeutic target for overcoming radioresistance.
Main Methods:
- Bioinformatic analysis of public databases and retrospective analysis of a 30-patient ESCC cohort with immunohistochemistry.
- In vitro studies using ESCC cell lines to assess Eg5 expression, clinicopathological features, and patient survival.
- Measurement of ROS generation via flow cytometry and DNA damage via γH2AX foci detection after K858 and radiotherapy treatment.
Main Results:
- Eg5 mRNA and protein were significantly upregulated in ESCC compared to normal tissues, correlating with smoking history, poor grade, and reduced survival.
- Eg5 expression negatively correlated with E-cadherin, indicating its role in epithelial-mesenchymal transition.
- K858 treatment amplified radiotherapy-induced ROS generation and γH2AX foci, demonstrating Eg5 inhibition enhances efficacy via oxidative DNA injury.
Conclusions:
- Combining K858 and radiotherapy is a promising strategy for ESCC treatment by boosting oxidative stress and DNA damage.
- Eg5 serves as an independent prognostic marker and a viable therapeutic target for overcoming radioresistance in ESCC.
- Further validation in large-scale prospective studies is needed, but Eg5 inhibition with K858 presents a novel approach to sensitize ESCC to radiotherapy.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...